USFDA12 Sept 2026, 04:40 pm
Dishman Carbogen Amcis Subsidiary Clears US FDA Inspection With Zero Observations
AI Summary
Dishman Carbogen Amcis Ltd announced that its wholly-owned subsidiary, CARBOGEN AMCIS AG's manufacturing site in Vionnaz, Switzerland, has successfully completed a U.S. Food and Drug Administration (FDA) inspection. The inspection concluded without any Form 483 observations, highlighting the company's strong commitment to quality standards across its global operations. This successful audit reinforces the regulatory compliance of the company's facilities, which are approved by major regulatory agencies worldwide.
Key Highlights
- Subsidiary's Swiss site passed US FDA inspection.
- No observations (Form 483) were issued.
- Demonstrates strong company-wide quality focus.
- Reinforces global regulatory compliance.
- All company sites approved by major agencies.
Price Impact
More from DCAL